Evidence map›Paper›PMID 39063646›Full record

ArticleLife (Basel, Switzerland)2024

Use of VESsel GENeration with Optical Coherence Tomography Angiography and Fluorescein Angiography for Detection and Quantification of Vascular Changes in Mild and Moderate Diabetic Retinopathy.

Mariana DuPont, Edmund Arthur, Yazen Shihab, Madelyn Kenny, Swetha Ravichandran, Patricia Parsons-Wingerter, Ruchi Vyas, Matthew C Murray, Marina Predovic, Shiyin Lim and 9 more

Abstract read
In one paragraph

Article in Life (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Mariana DuPontDepartment of Ophthalmology and Visual Sciences, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA.ORCID 0000-0001-7986-3383
Edmund ArthurSchool of Optometry, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Yazen ShihabBirmingham School of Medicine, University of Alabama, Birmingham, AL 35233, USA.
Madelyn KennySchool of Optometry, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Swetha RavichandranSchool of Optometry, University of Alabama at Birmingham, Birmingham, AL 35294, USA.ORCID 0000-0001-9846-4089
Patricia Parsons-WingerterNational Aeronautics and Space Administration (NASA), Washington, DC 20546, USA.
Ruchi VyasMori Associates, Ames Research Center, National Aeronautics and Space Administration (NASA), Moffett Field, CA 94035, USA.
Matthew C MurrayBlue Marble Space Institute of Science, Ames Research Center, NASA, Moffett Field, CA 94035, USA.
Marina PredovicBlue Marble Space Institute of Science, Ames Research Center, NASA, Moffett Field, CA 94035, USA.
Shiyin LimBlue Marble Space Institute of Science, Ames Research Center, NASA, Moffett Field, CA 94035, USA.
Nicole JacobsBlue Marble Space Institute of Science, Ames Research Center, NASA, Moffett Field, CA 94035, USA.
Sneha RameshBlue Marble Space Institute of Science, Ames Research Center, NASA, Moffett Field, CA 94035, USA.
Amanda VuBlue Marble Space Institute of Science, Ames Research Center, NASA, Moffett Field, CA 94035, USA.
Srinivaas SekaranBlue Marble Space Institute of Science, Ames Research Center, NASA, Moffett Field, CA 94035, USA.
Kakarla V ChalamDepartment of Ophthalmology, Loma Linda University Health Care, Loma Linda, CA 92354, USA.
Ramana S MoorthyAssociated Vitreoretinal and Uveitis Consultants, Indianapolis, IN 46290, USA.
Jason CrossonRetina Consultants of Alabama Birmingham, Birmingham, AL 35233, USA.
John MasonRetina Consultants of Alabama Birmingham, Birmingham, AL 35233, USA.
Maria B GrantDepartment of Ophthalmology and Visual Sciences, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA.

Funding

Visual Phenotyping CoreP30EY003039 · NEI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Paul Douglas Gamlin · 1985 to 2026
$16.9M
NITRIC OXIDE IN THE PATHOGENESIS OF DIABETIC RETINOPATHYR01EY012601 · NEI · UNIVERSITY OF FLORIDA · PI Julia V Busik, Maria Bartolomeo Grant · 1998 to 2026
$9.6M
LXR as a Novel Therapeutic Target in Diabetic RetinopathyR01EY025383 · NEI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BUSIK, JULIA V, GRANT, MARIA BARTOLOMEO · 2015 to 2024
$4.2M
Somatostatin blockade of CNS autonomic hyperactivity for treatment of diabetic retinopathyR01EY028037 · NEI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BOULTON, MICHAEL EDWIN, FRAZIER, CHARLES J · 2017 to 2020
$1.9M
ACE2 on gut barrier dysfunction and BRB disruptionR01EY032753 · NEI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Michael Edwin Boulton, Maria Bartolomeo Grant · 2022 to 2026
$1.8M
ACE2 Modulates the Bone Marrow- Gut Axis in Diabetic RetinopathyR01EY028858 · NEI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BOULTON, MICHAEL EDWIN, GRANT, MARIA BARTOLOMEO · 2018 to 2021
$1.6M
ARVO Genentech Career Development Award N/ANEI NIH HHS P30 EY003039NEI NIH HHS R01 EY012601NEI NIH HHS R01EY012601NEI NIH HHS R01EY025383NEI NIH HHS R01EY028037NEI NIH HHS R01EY028858NEI NIH HHS R01 EY032753NEI NIH HHS R01EY032753UAB DRC Pilot Grant N/AUAB ICAR Pilot Grant N/A
6 · The paper itself

Abstract

(1) Background: Previously, VESsel GENeration (VESGEN) software was used to map and quantify vascular changes observed on fluorescein angiography (FA) in subjects (n = 15 eyes) with retinal pathology ranging from mild non-proliferative diabetic retinopathy (NPDR) to proliferative diabetic retinopathy (PDR). In the current study, we used VESGEN for the assessment of individuals with early-stage NPDR imaged by FA (Cohort 1) and by optical coherence tomography angiography (OCTA; Cohort 2). (2) Methods: Cohort 1 included type 2 diabetics (T2D), represented 21 eyes (ranging from no DR to moderate DR), and also included nondiabetic controls (NDC; n = 15 eyes). Cohort 2 consisted of 23 eyes from T2D subjects (including no DR subjects and moderate DR subjects) and NDC (n = 18 eyes). (3) Results: In the FA-VESGEN study, total tortuosity (Tv) of microvessels (G ≥ 6) increased in T2D with mild DR compared to the controls. In contrast, the VESGEN analysis of OCTA images showed that vessel length (characterized as density) was lower in T2D subjects before the diagnosis of DR and following the diagnosis of DR when compared to the controls. Additionally, T2D showed a significant decrease in vessel area (density). (4) Conclusions: FA elucidated the vessel morphology of small-generation microvessels to a greater degree than OCTA; however, OCTA identified changes in vessel density better than FA. VESGEN analysis can be used with both standard FA and OCTA to facilitate our understanding of early events in DR, including before the clinical diagnosis of DR.

Indexed as

fluorescein angiographyimage processingoptical coherence tomography angiographyretinal imagingvascular segmentationVESGEN

Identifiers

PMID39063646
PMCPMC11277959

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.